Packaging / QRM Process

Recall of Hospira Injections

Source: FDA

Oct 03, 2013

Hospira is voluntarily recalling one lot of Metoclopramide Injection, USP, 10 mg/2 mL (5 mg/mL)and two lots of Ondansetron Injection, USP, 4 mg/2 mL, (2 mg/mL), according to the FDA. The recall follows a confirmed vial defect. Glass particulate matter (glass strands) were found to have become affixed to the inside of vial walls. The glass particulate might dislodge into the solution. There have been no reports of adverse effects associated with the lots in question. Read more.